Physician profile
Naveed Aslam
NPI 1235146002
$28,600.83
in general payments reported to CMS, 2019-2025
78 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,049 · 2020: $1,216 · 2021: $1,409 · 2022: $15K · 2023: $2,696 · 2024: $5,305 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Consulting Fee: $2,140 · Long Term Medical Supply Or Device Loan: $1,496 · Education: $235 · Travel and Lodging: $27.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.07 |
| Consulting Fee | $2,140.00 |
| Long Term Medical Supply Or Device Loan | $1,495.50 |
| Education | $234.98 |
| Travel and Lodging | $27.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $13,242.27 | 2019-2024 | Enhertu, Vanflyta |
| Genzyme Corporation | $2,803.22 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $2,451.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,137.82 | 2019-2024 | Calquence, Imfinzi, Lynparza |
| Genentech USA, INC. | $814.19 | 2019-2024 | Venclexta, Perjeta, Kadcyla |
| Amgen INC. | $589.45 | 2019-2023 | Blincyto, Kyprolis, Xgeva |
| Lilly USA, LLC | $481.33 | 2019-2024 | Verzenio, Jaypirca |
| Celgene Corporation | $427.88 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $384.74 | 2019-2024 | Rybrevant, Darzalex, Tecvayli |
| Astellas Pharma US INC | $383.93 | 2019-2024 | Padcev |
| Eisai INC. | $342.95 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $331.14 | 2019-2024 | Keytruda, Lynparza |
| Pfizer INC. | $328.49 | 2019-2024 | |
| Seagen INC. | $324.86 | 2020-2023 | Padcev, Tukysa, Tivdak |
| Gilead Sciences, INC. | $268.70 | 2019-2024 | Trodelvy |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.